Multiple Myeloma | Specialty

Optimizing the Use of Anti-BCMA Therapy in MM

July 18th 2018

The Promise of Anti-BCMA CAR T-Cell Therapy in MM

July 18th 2018

Evaluating MRD's Role in Multiple Myeloma

July 18th 2018

Using MRD to Determine Cure in Multiple Myeloma

July 18th 2018

Sequencing Through Multiple Lines of Therapy

July 18th 2018

Selecting a Proteasome Inhibitor in Multiple Myeloma

July 18th 2018

Switching IMiDs: The OPTIMISMM Trial's Impact on MM

July 18th 2018

Treatment Approaches in Relapsed Multiple Myeloma

July 18th 2018

Optimizing Early Sequencing and Treatment in MM

July 18th 2018

Extrapolating from Clinical Trials: Daratumumab in MM

July 18th 2018

Optimizing Therapy for High-Risk Newly Diagnosed MM

July 18th 2018

Newly Diagnosed MM: Is RVd Still Standard of Care?

July 18th 2018

Dr. Madduri on SWOG S0777 in Multiple Myeloma

July 16th 2018

Deepu Madduri, MD, assistant professor, Mount Sinai Hospital, discusses evidence supporting the use of a triplet regimen versus a doublet regimen in elderly and transplant ineligible patients with multiple myeloma.

Dr. Lesokhin Discusses Exciting Advances in Multiple Myeloma

July 14th 2018

Alexander M. Lesokhin, MD, assistant attending, Department of Medicine and Myeloma Service, Memorial Sloan Kettering Cancer Center, discusses some of the exciting advancements currently happening in the field of multiple myeloma.

Dr. Biran Discusses Treatment Discontinuation in Myeloma

July 13th 2018

Noa Biran, MD, physician, Multiple Myeloma Division, John Theurer Cancer Center, discusses treatment discontinuation in multiple myeloma.

PVd Regimen Highlighted as New Standard in Relapsed/Refractory Myeloma

July 13th 2018

Paul Richardson, MD, discusses the efficacy and tolerability of the combination of pomalidomide (Pomalyst), bortezomib (Velcade), and dexamethasone in patients with multiple myeloma.

Maintenance Ixazomib Improves PFS in Multiple Myeloma

July 11th 2018

Ixazomib (Ninlaro) improved progression-free survival compared with placebo as a maintenance therapy in adult patients with multiple myeloma who responded to high-dose therapy and autologous stem cell transplant.

Dr. Richardson on the Synergy Between Immunomodulators and Proteasome Inhibitors

July 6th 2018

Paul Richardson, MD, clinical program leader, director of clinical research, Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, RJ Corman Professor of Medicine, Harvard Medical School, discusses the synergy between immunomodulators and proteasome inhibitors in the treatment of patients with relapsed/refractory multiple myeloma (RRMM).

Expert Discusses Daratumumab Developments in Myeloma

July 6th 2018

Ajai Chari, MD, discusses the addition of daratumumab to carfilzomib and dexamethasone, as well as the potential impact of subcutaneous daratumumab in the treatment of patients with myeloma.

Dr. Chari on the Subgroup Analysis of MMY1001 in Multiple Myeloma

June 29th 2018

Ajai Chari, MD, associate professor of medicine, Hematology and Medical Oncology, Mount Sinai Hospital, discusses the subgroup analysis of MMY1001 in multiple myeloma.